NovaBridge Biosciences (NASDAQ:NBP) Chief Medical Officer Dennis Phillip Andrew has executed a sale of company securities, according to a newly filed Form 4 with the Securities and Exchange Commission. The transaction occurred against a backdrop of significant corporate developments, including the acquisition of Fast Track Designation for its drug candidate givastomig and the appointment of a new President and Chief Commercial Officer. Despite these advancements, the company's stock continues to trade near its 52-week low, reflecting ongoing market pressures.
On June 18, 2026, Mr. Andrew disposed of 8,494 ordinary shares at a price of $0.66 per share, totaling $5,606. These ordinary shares are represented by American Depositary Shares (ADSs), with 3,693 ADSs corresponding to the transaction. The reported sales price for the ADSs was $1.51 per ADS. Following this transaction, Mr. Andrew directly holds 157,941 ordinary shares, which are represented by 68,670 ADSs. The transaction comes as NovaBridge shares trade near their 52-week low of $1.46, with the stock down roughly 66% over the past six months to its current price of $1.53.
This sale followed an acquisition of 23,695 ordinary shares on June 17, 2026. These shares, represented by 10,302 ADSs, were acquired at a price of $0.0, typically indicating an exercise or vesting event. After this acquisition, Mr. Andrew held 166,435 ordinary shares, represented by 72,363 ADSs. Separately, on June 17, 2026, Mr. Andrew reported the disposition of 10,302 Restricted Share Units (RSUs). Each RSU represents a contingent right to receive one ADS. These RSUs were part of a larger grant of 164,840 RSUs made on June 17, 2024, which are scheduled to vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters. Following this RSU transaction, Mr. Andrew holds 82,422 Restricted Share Units, which are also represented by ADSs.
While individual executive transactions provide a snapshot of insider activity, the broader context for NovaBridge Biosciences involves both regulatory progress and strategic leadership changes. The company recently announced that the U.S. Food and Drug Administration granted Fast Track Designation to its drug givastomig. This designation applies to the combination of givastomig with nivolumab and chemotherapy, targeting patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas. The tumors in these patients are characterized by being Claudin 18.2 and PD-L1 positive. Givastomig is a bispecific antibody, and Phase 1b data has shown both efficacy and tolerability when combined with immunochemotherapy.
In parallel corporate developments, NovaBridge appointed Mark Hagler as President and Chief Commercial Officer. Hagler brings over 25 years of experience in the biopharmaceutical industry, having previously held a leadership position at Sun Pharmaceuticals Industries Limited. Additionally, H.C. Wainwright reiterated a Buy rating for NovaBridge, citing the durability of the company's drug candidate, VIS-101, which is under evaluation for wet age-related macular degeneration. The firm maintained a price target of $9.00, highlighting promising Phase 2a data for VIS-101.
Financially, according to InvestingPro analysis, the company holds more cash than debt on its balance sheet and maintains liquid assets exceeding short-term obligations. This liquidity position provides a buffer against operational uncertainties, though the stock's performance remains under pressure. The market's reaction to insider activity and corporate developments will be closely watched by investors assessing the risk-reward profile of NovaBridge Biosciences.